Novavax

822 articles with Novavax

• Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4) - Jan 25, 2023

  1/25/2023

  Novavax, Inc. announced that it has granted a non-qualified stock option and restricted stock units to John C. Jacobs, its newly appointed President and Chief Executive Officer, as a material inducement for his entry into employment with Novavax, effective as of January 23, 2023, the first date of his employment with Novavax.

• Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster

  1/18/2023

  Novavax, Inc. today announced that partner SK bioscience has received expanded manufacturing and marketing approval from the Korean Ministry of Food and Drug Safety (KMFDS) for Nuvaxovid™ (NVX-CoV2373) for use as a booster for active immunization to prevent COVID-19 in adults aged 18 and older.

• Novavax Names John C. Jacobs as New President & Chief Executive Officer

  1/9/2023

  Novavax, Inc. announced that John C. Jacobs will succeed Stanley C. Erck as President and Chief Executive Officer and a member of the Board of Directors.

• Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

  12/30/2022

  Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the initiation of a Phase 2 trial for its COVID-19-Influenza Combination and influenza stand-alone vaccine candidates.

• Novavax Announces Closing of $175.25 Million Offering of Convertible Senior Notes Due 2027 and $74.75 Million Public Offering of Common Stock

  12/28/2022

  Novavax, Inc. completed the closing of its previously announced offering of $150 million aggregate amount of 5.00% Senior Convertible Notes due 2027, and on December 23, 2022, the Company completed the closing of the initial purchasers' option to purchase up to an additional $25.25 million aggregate principal amount of the Notes, which was exercised in full.

• Novavax Announces Pricing of $65 Million Public Offering of Common Stock - December 16, 2022

  12/16/2022

  Novavax, Inc. announced the pricing of an underwritten public offering to sell 6,500,000 shares of its common stock at a public offering price of $10.00 per share, or $65 million worth of shares of its common stock.

• Novavax Announces Pricing of $150 Million Offering of Convertible Senior Notes

  12/16/2022

  Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the pricing of an offering of $150 million aggregate principal amount of its 5.00% convertible senior notes due 2027.

• Novavax Announces Proposed Offering of $125 Million of Convertible Senior Notes

  12/14/2022

  Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced a proposed offering of $125 million aggregate principal amount of convertible senior notes due 2027.

• Novavax Announces Proposed $125 Million Public Offering of Common Stock

  12/14/2022

  Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced a proposed underwritten public offering to sell up to $125 million of its common stock.

• Novavax Nuvaxovid COVID-19 Vaccine Approved in Canada for Use as a Primary Series in Adolescents

  12/7/2022

  Novavax, Inc. (Nasdaq: NVAX) today announced that Health Canada has approved a supplement to a New Drug Submission (sNDS) for Nuvaxovid™ (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series of two doses in adolescents aged 12 through 17.

• Novavax to Participate in BofA Securities 2022 Virtual Biotech SMID Cap Conference

  12/2/2022

  Novavax, Inc. today announced that it will participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference.

• World Health Organization Updates Emergency Use Listing for Novavax Nuvaxovid COVID-19 Vaccine as a Primary Series in Adolescents and as a Booster in Adults

  11/29/2022

  Novavax, Inc. announced that the World Health Organization has issued an updated Emergency Use Listing for Nuvaxovid™ COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 as a primary series of two doses in adolescents aged 12 through 17 and as a booster in adults aged 18 and older.

• Novavax Nuvaxovid COVID-19 Vaccine Receives Expanded Authorization in Canada as a Booster in Adults

  11/18/2022

  Novavax, Inc. (Nasdaq: NVAX) today announced that Health Canada has granted expanded authorization for Nuvaxovid™ (COVID-19 Vaccine (Recombinant protein, Adjuvanted)) (NVX-CoV2373) for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a homologous booster in adults aged 18 and older.

• Novavax to Participate in 2022 Jefferies London Healthcare Conference

  11/14/2022

  Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced that it will participate in the Jefferies London Healthcare Conference.

• Novavax Nuvaxovid™ COVID-19 Vaccine▼ Authorized in the United Kingdom for Use as a Booster in Adults

  11/9/2022

  Novavax, Inc. (Nasdaq: NVAX) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (U.K.) has expanded the conditional marketing authorization (CMA)i for Nuvaxovid™.

• Novavax Reports Third Quarter 2022 Financial Results and Operational Highlights

  11/8/2022

  Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2022.

• Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster

  11/8/2022

  Novavax, Inc. today announced topline results from its Phase 3 Boosting Trial for the SARS-CoV-2 rS Variant Vaccines (COVID-19) showing that the Company's BA.1 vaccine candidate (NVX-CoV2515) met the primary strain-change endpoint.

• Novavax Appoints Rick Rodgers to Board of Directors

  11/1/2022

  Novavax, Inc., a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, announced the appointment of Richard Rodgers, MBA to its board as an independent director.

• Novavax to Host Conference Call to Discuss Third Quarter 2022 Financial Results and Operational Highlights on November 8, 2022

  11/1/2022

  Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced it will report its third quarter 2022 financial results and operational highlights on Tuesday, November 8, 2022, following the close of U.S. financial markets.

• Novavax Showcases Data from Expanding Vaccine Portfolio at IDWeek 2022

  10/20/2022

  Novavax, Inc. (Nasdaq: NVAX) will present new data from the Phase 3 PREVENT-19 trial evaluating its protein-based COVID-19 vaccine (NVX-CoV2373) as a booster in adults, including a breakdown by age and by booster dose interval (8 and 11 months) at IDWeek 2022, October 20 to 22, 2022.